Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 6/20 | 0.47 |
| ▸ | JAK1 | P23458 | 6/20 | 0.47 |
| ▸ | JAK3 | P52333 | 5/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738095 | 0.92 | SYK (0.61) | SYKCYP2C9CYP2D6JAK2JAK1 | |
| SCHEMBL14738557 | 0.92 | SYK (0.61) | SYKCYP2C9CYP2D6JAK2JAK1 | |
| SCHEMBL14737556 | 0.84 | SYK (0.67) | SYKCYP2C9CYP2D6JAK2JAK1 | |
| SCHEMBL14737368 | 0.84 | SYK (0.78) | SYKCYP2C9CYP2D6JAK2JAK1 | |
| SCHEMBL14737952 | 0.84 | SYK (0.78) | SYKCYP2C9CYP2D6JAK2JAK1 | |
| SCHEMBL14738025 | 0.83 | JAK2 (0.63) | SYKCYP2C9CYP2D6JAK2JAK1 | |
| SCHEMBL14743763 | 0.81 | SYK (0.61) | SYKCYP2C9CYP2D6JAK2JAK1 | |
| SCHEMBL14737679 | 0.81 | SYK (0.67) | SYKCYP2C9CYP2D6JAK2JAK1 | |
| SCHEMBL14737064 | 0.80 | SYK (0.57) | SYKCYP2C9CYP2D6JAK2JAK1 | |
| SCHEMBL14738245 | 0.80 | SYK (0.57) | SYKCYP2C9CYP2D6JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | claimed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | SYK 1/4885CYP2C9 3710/4885CYP2D6 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.